Researchers in neuropsychopharmacology challenge conventional wisdom about antidepressants’ actions, revealing significant intracellular activity that influences their effectiveness. Utilizing advanced technologies, the study prompts a reevaluation of drug targeting and mechanisms, opening new avenues for treating depression.
FDA approves Purdue Pharma’s controversial new overdose-reversal medication
Purdue Pharma, the company best known for fueling the opioid crisis by misleadingly marketing the infamous painkiller OxyContin, received approval on Wednesday for a new
August 8, 2024